OmniUltra™: Leveraging Natural Immunity Beyond Antibodies Into Peptides

Reach new targets with in vivo-optimized peptides

OmniUltra is a versatile in vivo discovery platform that extends beyond traditional antibody modalities into the peptide space, enabling multiple therapeutic applications. It generates naturally optimized human immune antibody repertoires featuring cow-inspired ultralong CDRH3 domains, unlocking novel binding modes and access to challenging targets. OmniUltra also enables the isolation of picobodies™, the smallest known natural antibody-derived binding domain (4-6 kDa), one-third the size of a nanobody®. OmniUltra delivers pre-optimized specificity, affinity, and structural stability, streamlining hit-to-lead identification.

Not your average chickens

OmniUltra leverages uniquely engineered chickens that blend key features of human, cow, and avian immune systems to generate novel repertoires with ultralong CDRH3 regions for drug discovery. By harnessing the evolutionary distance advantage of a chicken host, OmniUltra achieves robust and expanded epitope coverage of human proteins, delivering differentiated antibody repertoires with exceptional optionality and versatility for next-generation therapeutics.

One discovery platform. Beyond antibodies. Into peptides.

OmniUltra redefines biotherapeutic discovery by generating both antibodies and picobodies (structured peptides), and is ideal for applications such as bispecifics, multispecifics, CAR-T, radioligands, and stand-alone peptide therapeutics.

Uniquely access a wide array of targets

OmniUltra accesses hard-to-reach epitopes using a novel, ultralong CDRH3 binding domain with a protruding paratope, combined with the evolutionary advantage of a chicken host for expanded epitope coverage of human targets.

Flexibility for structured peptides and custom conjugates

Use picobodies alone or tethered to other scaffolds to develop targeted conjugates and multispecifics, leveraging their small size and autonomous binding capability.

Unlock differentiated modes of action

Target alternative biological pathways by binding recessed epitopes with OmniUltra’s unique scaffold that may be inaccessible to conventional antibodies.

In vivo optimized

Generate diverse, target-specific repertoires of structured peptides, powered by natural immune systems to capture the characteristics and binding profiles that work.

OmniUltra repertoires are enriched for pre-optimized sequences

Generate unique human antibodies or picobodies with built-in specificity, affinity, and stability, accelerating hit-to-lead identification.

OmniUltra enables multiple therapeutic applications:

  • Radiopharmaceutical therapeutics: With their small size and rapid clearance, OmniUltra-derived picobodies are ideally suited for radioligands used in targeted imaging and therapy.
  • Bispecific and multispecific antibody therapeutics: With a diverse array of conjugation possibilities, OmniUltra enables the versatile construction of bi- and multispecific antibodies for enhanced therapeutic impact.
  • CAR-T therapy: OmniUltra’s picobodies provide flexible binding units for CAR-T constructs or targeted delivery molecules, enabling precise recognition and destruction of cancer cells.
  • Peptide therapeutics: In vivo generation of functional picobodies as structured peptides offers a unique and versatile approach to peptide discovery, expanding beyond traditional antibody modalities.